242 related articles for article (PubMed ID: 11483392)
1. Lafora's disease: towards a clinical, pathologic, and molecular synthesis.
Minassian BA
Pediatr Neurol; 2001 Jul; 25(1):21-9. PubMed ID: 11483392
[TBL] [Abstract][Full Text] [Related]
2. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy.
Minassian BA; Ianzano L; Meloche M; Andermann E; Rouleau GA; Delgado-Escueta AV; Scherer SW
Neurology; 2000 Aug; 55(3):341-6. PubMed ID: 10932264
[TBL] [Abstract][Full Text] [Related]
3. [Lafora's disease presenting with progressive myoclonus epilepsy].
Béjot Y; Lemesle-Martin M; Contégal F; Graule-Petot A; Thauvin C; Aubriot-Lorton MH; Moreau T; Giroud M
Rev Neurol (Paris); 2007 Oct; 163(10):975-8. PubMed ID: 18033035
[TBL] [Abstract][Full Text] [Related]
4. [Progressive myoclonic epilepsy secondary to Lafora's body disease].
Potes T; Galicchio S; Rosso B; Besocke G; García MDC; Avalos JC
Medicina (B Aires); 2018; 78(6):436-439. PubMed ID: 30504111
[TBL] [Abstract][Full Text] [Related]
5. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Ganesh S; Delgado-Escueta AV; Suzuki T; Francheschetti S; Riggio C; Avanzini G; Rabinowicz A; Bohlega S; Bailey J; Alonso ME; Rasmussen A; Thomson AE; Ochoa A; Prado AJ; Medina MT; Yamakawa K
Hum Mol Genet; 2002 May; 11(11):1263-71. PubMed ID: 12019207
[TBL] [Abstract][Full Text] [Related]
6. The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies.
Ganesh S; Tsurutani N; Suzuki T; Hoshii Y; Ishihara T; Delgado-Escueta AV; Yamakawa K
Biochem Biophys Res Commun; 2004 Jan; 313(4):1101-9. PubMed ID: 14706656
[TBL] [Abstract][Full Text] [Related]
7. Novel NHLRC1 mutations and genotype-phenotype correlations in patients with Lafora's progressive myoclonic epilepsy.
Singh S; Sethi I; Francheschetti S; Riggio C; Avanzini G; Yamakawa K; Delgado-Escueta AV; Ganesh S
J Med Genet; 2006 Sep; 43(9):e48. PubMed ID: 16950819
[TBL] [Abstract][Full Text] [Related]
8. [Lafora disease with a fatal outcome].
Krakhmal NV; Vasilchenko DV; Vtorushin SV
Arkh Patol; 2022; 84(6):61-66. PubMed ID: 36469720
[TBL] [Abstract][Full Text] [Related]
9. Two novel mutations in the EPM2A gene in a Korean patient with Lafora's progressive myoclonus epilepsy.
Ki CS; Kong SY; Seo DW; Hong SB; Kim HJ; Kim JW
J Hum Genet; 2003; 48(1):51-4. PubMed ID: 12560877
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy.
Ganesh S; Puri R; Singh S; Mittal S; Dubey D
J Hum Genet; 2006; 51(1):1-8. PubMed ID: 16311711
[TBL] [Abstract][Full Text] [Related]
11. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.
Chan EM; Ackerley CA; Lohi H; Ianzano L; Cortez MA; Shannon P; Scherer SW; Minassian BA
Hum Mol Genet; 2004 Jun; 13(11):1117-29. PubMed ID: 15102711
[TBL] [Abstract][Full Text] [Related]
12. A case of Lafora's disease associated with cardiac arrhythmia.
Oksel F; Tekgül H; Genç S; Ozyürek R; Akalin T; Tütütüncüoğlu S
J Child Neurol; 1999 Nov; 14(11):745-6. PubMed ID: 10593553
[TBL] [Abstract][Full Text] [Related]
13. Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease.
Minassian BA
Adv Neurol; 2002; 89():199-210. PubMed ID: 11968446
[No Abstract] [Full Text] [Related]
14. Advances in lafora progressive myoclonus epilepsy.
Delgado-Escueta AV
Curr Neurol Neurosci Rep; 2007 Sep; 7(5):428-33. PubMed ID: 17764634
[TBL] [Abstract][Full Text] [Related]
15. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.
Minassian BA; Lee JR; Herbrick JA; Huizenga J; Soder S; Mungall AJ; Dunham I; Gardner R; Fong CY; Carpenter S; Jardim L; Satishchandra P; Andermann E; Snead OC; Lopes-Cendes I; Tsui LC; Delgado-Escueta AV; Rouleau GA; Scherer SW
Nat Genet; 1998 Oct; 20(2):171-4. PubMed ID: 9771710
[TBL] [Abstract][Full Text] [Related]
16. A novel exon 3 mutation in a Tunisian patient with Lafora's disease.
Khiari HM; Lesca G; Malafosse A; Mrabet A
J Neurol Sci; 2011 May; 304(1-2):136-7. PubMed ID: 21371719
[TBL] [Abstract][Full Text] [Related]
17. [Progressive myoclonic epilepsy type Lafora].
Chemaly R; Checrallah A; Trak-Smayra V; El-Kallab K; Chemaly E
J Med Liban; 2001; 49(3):170-2. PubMed ID: 12187920
[TBL] [Abstract][Full Text] [Related]
18. Laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase.
Minassian BA; Andrade DM; Ianzano L; Young EJ; Chan E; Ackerley CA; Scherer SW
Ann Neurol; 2001 Feb; 49(2):271-5. PubMed ID: 11220751
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of zonisamide in Lafora's disease case and brief review of its use in progressive myoclonic epilepsy].
Rubio-Nazábal E; Álvarez-Pérez P; Cores-Bartolomé C; Lema-Facal T
Rev Neurol; 2022 Sep; 75(6):159-163. PubMed ID: 36098450
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
